Compare CRI & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRI | SANA |
|---|---|---|
| Founded | 1865 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 983.4M |
| IPO Year | 2003 | 2021 |
| Metric | CRI | SANA |
|---|---|---|
| Price | $31.54 | $4.14 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $29.50 | $7.83 |
| AVG Volume (30 Days) | 986.0K | ★ 4.2M |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $2,832,687,000.00 | N/A |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.38 | $1.26 |
| 52 Week High | $58.13 | $7.30 |
| Indicator | CRI | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 51.85 |
| Support Level | $31.00 | $3.93 |
| Resistance Level | $32.44 | $4.35 |
| Average True Range (ATR) | 1.34 | 0.36 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 61.26 | 81.09 |
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.